Royalty Pharma Plc share price today
(NASDAQ: RPRX)

Name: Royalty Pharma Plc Share Price Today (NASDAQ: RPRX) - Royalty Pharma Plc Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Royalty Pharma Plc share price is $30.6 & ₹2,646.59 as on 24 Jan 2025, 2.30 'hrs' IST

$30.6

▲

0.52

(1.73%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Royalty Pharma Plc share price in Dollar and Rupees. Guide to invest in Royalty Pharma Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Royalty Pharma Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Royalty Pharma Plc share price movements

Today's Low: $30.05
Today's High: $30.64
$30.60
1.8%
Downside
Day's Volatility :1.91%
Upside
0.11%
52 Weeks Low: $24.05
52 Weeks High: $31.66
$30.60
21.41%
Downside
52 Weeks Volatility :24.02%
Upside
3.33%

Royalty Pharma Plc Returns

Period	Royalty Pharma Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	11.61%	-5.5%	0.0%
6 Months	4.48%	-4.3%	0.0%
1 Year	3.33%	1.6%	0.0%
3 Years	-23.13%	9.8%	-11.0%

Royalty Pharma Plc Key Statistics

in dollars & INR

Previous Close	$30.08
Open	$30.13
Today's High	$30.635
Today's Low	$30.05
Market Capitalization	$17.9B
Today's Volume	$3.5M
52 Week High	$31.655
52 Week Low	$24.05
Revenue TTM	$2.3B
EBITDA	$1.5B
Earnings Per Share (EPS)	$2.54
PE Ratio	11.93
Dividend Yield	2.86%
Profit Margin	50.53%
Quarterly Earnings Growth YOY	6.59%
Return On Equity TTM	17.28%

How to invest in Royalty Pharma Plc Stock (RPRX) from India?

It is very easy for Indian residents to invest directly in Royalty Pharma Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Royalty Pharma Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Royalty Pharma Plc or RPRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Royalty Pharma Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Royalty Pharma Plc shares which would translate to 0.028 fractional shares of Royalty Pharma Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Royalty Pharma Plc, in just a few clicks!

Returns in Royalty Pharma Plc for Indian investors in Rupees

Investment Value

₹1,00,000

Royalty Pharma Plc investment value today

Current value as on today

₹1,09,173

Returns

₹9,173

(+9.17%)

Returns from Royalty Pharma Plc Stock

₹5,119 (+5.12%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Royalty Pharma Plc

105.56%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Investment in Royalty Pharma Plc from India has grown in the last 30 days as on Jan 24, 2025. 105.56% more purchase transactions for Royalty Pharma Plc in the last 30 days versus the previous period.

-5%

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Royalty Pharma Plc on INDmoney from India has reduced in the last 30 days as on Jan 24, 2025. -5% less investors are searching Royalty Pharma Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Royalty Pharma Plc

Morgan Stanley - Brokerage Accounts
9.25%
Vanguard Group Inc
8.46%
FMR Inc
6.28%
BlackRock Inc
5.02%
Baillie Gifford & Co Limited.
3.63%
Viking Global Investors LP
2.72%

Analyst Recommendation on Royalty Pharma Plc

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Royalty Pharma Plc(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Royalty Pharma Plc

What analysts predicted

Upside of 32.88%

Target:

$40.66

Current:

$30.60

Insights on Royalty Pharma Plc

Price Movement
In the last 1 month, RPRX stock has moved up by 19.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 537.26M → 564.69M (in $), with an average increase of 4.9% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 4.77M → 543.98M (in $), with an average increase of 88.3% per quarter
RPRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 38.1%
RPRX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 118.5%
Price to Sales
ForRPRX every $1 of sales, investors are willing to pay $6.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.1 for every $1 of sales.

Royalty Pharma Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.8B	↑ 12.33%
Net Income	$1.4B	↑ 13.86%
Net Profit Margin	76.76%	↑ 1.04%

	FY19	Y/Y Change
Revenue	$1.8B	↑ 1.08%
Net Income	$2.3B	↑ 70.46%
Net Profit Margin	129.45%	↑ 52.69%

	FY20	Y/Y Change
Revenue	$2.1B	↑ 16.96%
Net Income	$495.2M	↓ 78.91%
Net Profit Margin	23.34%	↓ 106.11%

	FY21	Y/Y Change
Revenue	$2.3B	↑ 7.89%
Net Income	$478.8M	↓ 3.32%
Net Profit Margin	20.91%	↓ 2.43%

	FY22	Y/Y Change
Revenue	$2.2B	↓ 2.28%
Net Income	$42.8M	↓ 91.05%
Net Profit Margin	1.91%	↓ 19.0%

	FY23	Y/Y Change
Revenue	$2.4B	↑ 5.24%
Net Income	$1.1B	↑ 2549.5%
Net Profit Margin	48.2%	↑ 46.29%

	Q2 FY23	Q/Q Change
Revenue	$538.2M	↓ 21.31%
Net Income	$227.6M	↓ 33.2%
Net Profit Margin	42.29%	↓ 7.53%

	Q3 FY23	Q/Q Change
Revenue	$536.3M	↓ 0.35%
Net Income	$72.1M	↓ 68.32%
Net Profit Margin	13.45%	↓ 28.84%

	Q4 FY23	Q/Q Change
Revenue	$596.0M	↑ 11.13%
Net Income	$494.3M	↑ 585.5%
Net Profit Margin	82.94%	↑ 69.49%

	Q1 FY24	Q/Q Change
Revenue	$568.0M	↓ 4.7%
Net Income	$4.8M	↓ 99.03%
Net Profit Margin	0.84%	↓ 82.1%

	Q2 FY24	Q/Q Change
Revenue	$537.3M	↓ 5.41%
Net Income	$102.0M	↑ 2034.87%
Net Profit Margin	18.99%	↑ 18.15%

	Q3 FY24	Q/Q Change
Revenue	$564.7M	↑ 5.1%
Net Income	$544.0M	↑ 433.3%
Net Profit Margin	96.33%	↑ 77.34%

	FY18	Y/Y Change
Profit	$1.7B	↑ 3.82%

	FY19	Y/Y Change
Profit	$794.9M	↓ 52.08%

	FY20	Y/Y Change
Profit	$2.0B	↑ 155.86%

	FY21	Y/Y Change
Profit	$2.3B	↑ 11.44%

	FY22	Y/Y Change
Profit	$2.2B	↓ 1.54%

	FY23	Y/Y Change
Profit	$1.8B	↓ 19.61%

	Q2 FY23	Q/Q Change
Profit	$297.0M	↓ 47.45%

	Q3 FY23	Q/Q Change
Profit	$259.2M	↓ 12.73%

	Q4 FY23	Q/Q Change
Profit	$519.5M	↑ 100.44%

	Q1 FY24	Q/Q Change
Profit	$-15.6M	↓ 103.01%

	Q2 FY24	Q/Q Change
Profit	$531.3M	↓ 3500.76%

	Q3 FY24	Q/Q Change
Profit	$563.0M	↑ 5.98%

	FY18	Y/Y Change
Operating Cash Flow	$1.6B	↑ 14.1%
Investing Cash Flow	$303.4M	↓ 119.11%
Financing Cash Flow	$-1.4B	↑ 1018.91%

	FY19	Y/Y Change
Operating Cash Flow	$1.7B	↑ 3.02%
Investing Cash Flow	$-2.2B	↓ 809.77%
Financing Cash Flow	$-1.2B	↓ 13.59%

	FY20	Y/Y Change
Operating Cash Flow	$2.0B	↑ 22.04%
Investing Cash Flow	$-2.8B	↑ 28.12%
Financing Cash Flow	$1.5B	↓ 224.79%

	FY21	Y/Y Change
Operating Cash Flow	$2.0B	↓ 0.84%
Investing Cash Flow	$-1.9B	↓ 32.22%
Financing Cash Flow	$385.1M	↓ 74.1%

	FY22	Y/Y Change
Operating Cash Flow	$2.1B	↑ 6.27%
Investing Cash Flow	$-1.0B	↓ 44.96%
Financing Cash Flow	$-944.9M	↓ 345.35%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$607.8M	↓ 41.21%
Investing Cash Flow	$-63.4M	↓ 88.64%
Financing Cash Flow	$-347.0M	↑ 64.94%

Royalty Pharma Plc Technicals Summary

Sell

Neutral

Buy

Royalty Pharma Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Royalty Pharma Plc Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Royalty Pharma Plc	19.22%	4.48%	3.33%	-23.13%	-32.4%
Biontech Se	0.91%	34.01%	18.85%	-26.4%	246.9%
Regeneron Pharmaceuticals, Inc.	-4.82%	-36.95%	-28.33%	12.74%	100.35%
Vertex Pharmaceuticals Incorporated	4.86%	-13.58%	-0.46%	88.45%	88.24%
Alnylam Pharmaceuticals, Inc.	9.57%	13.5%	44.91%	103.56%	127.75%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Royalty Pharma Plc	11.93	11.93	6.67	3.95	0.17	0.06	0.03	15.4
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Royalty Pharma Plc	Buy	$17.9B	-32.4%	11.93	50.53%
Biontech Se	Buy	$28.1B	246.9%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	100.35%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	88.24%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	127.75%	NA	-15.86%

Royalty Pharma Plc Dividend announcements

Royalty Pharma Plc Dividends March, 2025
In the quarter ending March,2025. Royalty Pharma Plc has declared dividend of $0.22
Read More

About Royalty Pharma Plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Organization	Royalty Pharma Plc
Employees	0
CEO	Mr. Pablo Gerardo Legorreta
Industry	Health Technology

Management People of Royalty Pharma Plc

Name	Title
Mr. Pablo Gerardo Legorreta	Founder, Chairman of the Board & CEO
Mr. Terrance P. Coyne	Executive VP & CFO
Mr. George Wingate Lloyd	Executive VP of Investments & Chief Legal Officer
Mr. Christopher Hite	Vice Chairman & Executive VP
Dr. Marshall Jonathan Urist M.D., Ph.D.	Executive Vice President of Research & Investments
Mr. Arthur Richard McGivern J.D.	Executive Vice President of Investments & General Counsel
Mr. Ashwin Pai M.D.	Executive Vice President of Investments
Ms. Kristin Stafford	Senior VP & Chief Accounting Officer
Mr. Eric Cornelius Schneider	Senior VP & Chief Technology Officer
Dr. James Folmar Reddoch Ph.D.	Executive VP of Investments & Chief Scientific Officer

Important FAQs about investing in Royalty Pharma Plc (RPRX) from India :

What is Royalty Pharma Plc share price today?

Royalty Pharma Plc share price today stands at $30.60, Open: $30.13 ; Previous Close: $30.08 ; High: $30.64 ; Low: $30.05 ; 52 Week High: $31.66 ; 52 Week Low: $24.05. The stock opens at $30.13, after a previous close of $30.08. The stock reached a daily high of $30.64 and a low of $30.05, with a 52-week high of $31.66 and a 52-week low of $24.05.

Can Indians buy Royalty Pharma Plc shares?

Yes, Indians can invest in the Royalty Pharma Plc (RPRX) from India.

With INDmoney, you can buy Royalty Pharma Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Royalty Pharma Plc at zero transaction cost.

How can I buy Royalty Pharma Plc shares from India?

It is very easy to buy Royalty Pharma Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Royalty Pharma Plc be purchased?

Yes, you can buy fractional shares of Royalty Pharma Plc with INDmoney app.

What are the documents required to start investing in Royalty Pharma Plc stocks?

To start investing in Royalty Pharma Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.